Cooper Companies
- Home ›
- US ›
- Healthcare
The Cooper Companies, Inc. operates as a medical device company worldwide. The last earnings update was 71 days ago. More info.
Add to Portfolio Compare Print
COO Share Price and Events
7 Day Returns
1 Year Returns
COO Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Cooper Companies (COO) | -0.2% | 0.6% | 4.2% | 26% | 82.5% | 123.8% |
| US Medical Equipment | -3.8% | -3.9% | -1.1% | 10% | 54.1% | 90.5% |
| US Market | -3.9% | -3.6% | 1.8% | 1.4% | 35.8% | 40.8% |
1 Year Return vs Industry and Market
- COO outperformed the Medical Equipment industry which returned 10% over the past year.
- COO outperformed the Market in United States of America which returned 1.4% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Cooper Companies
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Cooper Companies.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 15 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.7% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.9 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.896 (1 + (1- 21%) (14.85%)) |
1.001 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.001 * 5.96%) |
8.69% |
Discounted Cash Flow Calculation for NYSE:COO using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Cooper Companies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.69%) |
|
|---|---|---|---|
| 2019 | 590.11 | Analyst x3 | 542.90 |
| 2020 | 591.02 | Analyst x3 | 500.25 |
| 2021 | 696.00 | Analyst x2 | 541.98 |
| 2022 | 791.50 | Analyst x1 | 567.05 |
| 2023 | 862.16 | Analyst x1 | 568.26 |
| 2024 | 920.83 | Est @ 6.81% | 558.39 |
| 2025 | 972.23 | Est @ 5.58% | 542.40 |
| 2026 | 1,018.19 | Est @ 4.73% | 522.60 |
| 2027 | 1,060.21 | Est @ 4.13% | 500.65 |
| 2028 | 1,099.53 | Est @ 3.71% | 477.68 |
| Present value of next 10 years cash flows | $5,322.17 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $1,099.53 × (1 + 2.73%) ÷ (8.69% – 2.73%) |
$18,938.27 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $18,938.27 ÷ (1 + 8.69%)10 |
$8,227.53 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $5,322.17 + $8,227.53 |
$13,549.70 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $13,549.70 / 49.37 |
$274.43 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $274.43 |
| Current discount | Discount to share price of
$290.76
= -1 x ($290.76 - $274.43) / $274.43 |
-6% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Cooper Companies is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Cooper Companies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Cooper Companies's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-01-31) in USD | $7.43 |
| NYSE:COO Share Price ** | NYSE (2019-05-15) in USD | $290.76 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 64 Publicly-Listed Medical Equipment Companies | 38.98x |
| United States of America Market PE Ratio | Median Figure of 3,087 Publicly-Listed Companies | 17.79x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Cooper Companies.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:COO Share Price ÷ EPS (both in USD) = 290.76 ÷ 7.43 |
39.13x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cooper Companies is overvalued based on earnings compared to the US Medical Equipment industry average.
- Cooper Companies is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Cooper Companies's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 39.13x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts |
17.5%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 55 Publicly-Listed Medical Equipment Companies | 2.21x |
| United States of America Market PEG Ratio | Median Figure of 2,113 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 39.13x ÷ 17.5% |
2.24x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cooper Companies is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Cooper Companies's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-01-31) in USD | $69.48 |
| NYSE:COO Share Price * | NYSE (2019-05-15) in USD | $290.76 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 182 Publicly-Listed Medical Equipment Companies | 4.28x |
| United States of America Market PB Ratio | Median Figure of 5,195 Publicly-Listed Companies | 1.83x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:COO Share Price ÷ Book Value per Share (both in USD) = 290.76 ÷ 69.48 |
4.18x |
* Primary Listing of Cooper Companies.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cooper Companies is good value based on assets compared to the US Medical Equipment industry average.
Value checks
We assess Cooper Companies's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Cooper Companies has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Cooper Companies's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Cooper Companies's earnings growth is expected to exceed the United States of America market average.
- Cooper Companies's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:COO Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts | 17.5% |
| NYSE:COO Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts | 6.2% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 21.5% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 8.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-10-31 | ||||
| 2022-10-31 | 3,193 | 1 | ||
| 2021-10-31 | 3,013 | 923 | 643 | 7 |
| 2020-10-31 | 2,832 | 822 | 556 | 15 |
| 2019-10-31 | 2,656 | 761 | 475 | 15 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-01-31 | 2,571 | 745 | 366 |
| 2018-10-31 | 2,533 | 669 | 140 |
| 2018-07-31 | 2,443 | 631 | 128 |
| 2018-04-30 | 2,339 | 551 | 131 |
| 2018-01-31 | 2,230 | 511 | 175 |
| 2017-10-31 | 2,139 | 594 | 373 |
| 2017-07-31 | 2,096 | 588 | 345 |
| 2017-04-30 | 2,055 | 562 | 329 |
| 2017-01-31 | 2,016 | 529 | 298 |
| 2016-10-31 | 1,967 | 510 | 274 |
| 2016-07-31 | 1,904 | 421 | 250 |
| 2016-04-30 | 1,851 | 388 | 207 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
All data from Cooper Companies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-10-31 | ||||
| 2022-10-31 | 13.15 | 13.15 | 13.15 | 1.00 |
| 2021-10-31 | 12.60 | 14.20 | 11.07 | 6.00 |
| 2020-10-31 | 11.05 | 12.55 | 9.27 | 11.00 |
| 2019-10-31 | 9.41 | 10.51 | 7.55 | 11.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-01-31 | 7.43 |
| 2018-10-31 | 2.85 |
| 2018-07-31 | 2.61 |
| 2018-04-30 | 2.67 |
| 2018-01-31 | 3.57 |
| 2017-10-31 | 7.63 |
| 2017-07-31 | 7.05 |
| 2017-04-30 | 6.75 |
| 2017-01-31 | 6.13 |
| 2016-10-31 | 5.65 |
| 2016-07-31 | 5.16 |
| 2016-04-30 | 4.27 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Cooper Companies's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Cooper Companies has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Cooper Companies performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Cooper Companies's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Cooper Companies's 1-year earnings growth exceeds its 5-year average (109.4% vs -3.4%)
- Cooper Companies's earnings growth has exceeded the US Medical Equipment industry average in the past year (109.4% vs 31.9%).
Earnings and Revenue History
All data from Cooper Companies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-01-31 | 2,570.90 | 365.60 | 977.90 | 87.00 |
| 2018-10-31 | 2,532.80 | 139.90 | 964.60 | 84.80 |
| 2018-07-31 | 2,442.80 | 127.80 | 916.20 | 80.70 |
| 2018-04-30 | 2,338.80 | 130.60 | 872.30 | 75.70 |
| 2018-01-31 | 2,229.90 | 174.60 | 822.60 | 71.70 |
| 2017-10-31 | 2,139.00 | 372.90 | 785.30 | 69.20 |
| 2017-07-31 | 2,096.10 | 344.80 | 756.20 | 68.30 |
| 2017-04-30 | 2,054.90 | 329.10 | 739.40 | 66.70 |
| 2017-01-31 | 2,016.30 | 298.30 | 725.50 | 66.60 |
| 2016-10-31 | 1,966.80 | 273.90 | 710.90 | 65.40 |
| 2016-07-31 | 1,903.74 | 250.08 | 678.74 | 63.26 |
| 2016-04-30 | 1,850.61 | 207.13 | 665.63 | 63.76 |
| 2016-01-31 | 1,801.49 | 193.74 | 655.71 | 63.68 |
| 2015-10-31 | 1,797.10 | 203.50 | 661.00 | 65.00 |
| 2015-07-31 | 1,809.52 | 197.63 | 658.52 | 66.61 |
| 2015-04-30 | 1,780.33 | 240.75 | 654.84 | 66.28 |
| 2015-01-31 | 1,757.97 | 259.19 | 647.66 | 65.96 |
| 2014-10-31 | 1,717.78 | 269.86 | 638.62 | 65.66 |
| 2014-07-31 | 1,660.83 | 296.47 | 631.74 | 63.90 |
| 2014-04-30 | 1,639.64 | 297.35 | 622.68 | 62.69 |
| 2014-01-31 | 1,610.67 | 293.33 | 617.57 | 60.89 |
| 2013-10-31 | 1,587.73 | 296.15 | 610.14 | 58.83 |
| 2013-07-31 | 1,570.57 | 310.67 | 600.95 | 57.13 |
| 2013-04-30 | 1,537.47 | 288.60 | 592.64 | 55.42 |
| 2013-01-31 | 1,498.72 | 268.38 | 578.91 | 53.96 |
| 2012-10-31 | 1,445.14 | 248.34 | 564.90 | 51.73 |
| 2012-07-31 | 1,409.74 | 233.06 | 542.23 | 49.35 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Cooper Companies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Cooper Companies used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
- Cooper Companies has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Cooper Companies's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Cooper Companies has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Cooper Companies's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Cooper Companies's finances.
The net worth of a company is the difference between its assets and liabilities.
- Cooper Companies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Cooper Companies's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Cooper Companies Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-01-31 | 3,425.50 | 2,132.40 | 146.60 |
| 2018-10-31 | 3,307.80 | 2,022.80 | 77.70 |
| 2018-07-31 | 3,226.60 | 2,294.20 | 155.60 |
| 2018-04-30 | 3,188.00 | 2,483.70 | 164.90 |
| 2018-01-31 | 3,156.40 | 2,402.50 | 91.70 |
| 2017-10-31 | 3,175.80 | 1,172.70 | 88.80 |
| 2017-07-31 | 3,093.30 | 1,213.40 | 46.00 |
| 2017-04-30 | 2,939.80 | 1,386.90 | 121.30 |
| 2017-01-31 | 2,819.40 | 1,424.50 | 91.10 |
| 2016-10-31 | 2,695.90 | 1,333.70 | 100.80 |
| 2016-07-31 | 2,737.40 | 1,444.07 | 62.61 |
| 2016-04-30 | 2,744.78 | 1,441.37 | 44.46 |
| 2016-01-31 | 2,606.73 | 1,377.32 | 16.05 |
| 2015-10-31 | 2,673.90 | 1,349.21 | 16.43 |
| 2015-07-31 | 2,693.94 | 1,307.86 | 17.01 |
| 2015-04-30 | 2,615.74 | 1,347.71 | 17.91 |
| 2015-01-31 | 2,516.99 | 1,395.34 | 16.43 |
| 2014-10-31 | 2,588.44 | 1,382.35 | 25.22 |
| 2014-07-31 | 2,676.28 | 348.24 | 173.79 |
| 2014-04-30 | 2,562.08 | 336.12 | 82.66 |
| 2014-01-31 | 2,453.91 | 346.84 | 28.83 |
| 2013-10-31 | 2,423.49 | 346.36 | 77.39 |
| 2013-07-31 | 2,437.64 | 245.83 | 25.48 |
| 2013-04-30 | 2,336.50 | 323.40 | 14.44 |
| 2013-01-31 | 2,249.55 | 411.27 | 14.45 |
| 2012-10-31 | 2,213.16 | 377.61 | 12.84 |
| 2012-07-31 | 2,096.65 | 484.38 | 12.73 |
- Cooper Companies's level of debt (62.3%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (14.1% vs 62.3% today).
- Debt is well covered by operating cash flow (34.9%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 6.1x coverage).
Financial health checks
We assess Cooper Companies's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Cooper Companies has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Cooper Companies's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Cooper Companies
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Cooper Companies's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.46%).
- Cooper Companies's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 1997 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-10-31 | ||
| 2022-10-31 | ||
| 2021-10-31 | 0.06 | 2.00 |
| 2020-10-31 | 0.06 | 3.00 |
| 2019-10-31 | 0.06 | 3.00 |
| Date (Data in $) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-01-07 | 0.060 | 0.021 |
| 2018-12-21 | 0.060 | 0.024 |
| 2018-12-06 | 0.060 | 0.024 |
| 2018-07-12 | 0.060 | 0.023 |
| 2018-06-08 | 0.060 | 0.025 |
| 2018-06-07 | 0.060 | 0.026 |
| 2018-01-04 | 0.060 | 0.026 |
| 2017-12-22 | 0.060 | 0.027 |
| 2017-12-07 | 0.060 | 0.026 |
| 2017-09-01 | 0.060 | 0.025 |
| 2017-08-31 | 0.060 | 0.025 |
| 2017-06-02 | 0.060 | 0.025 |
| 2017-06-01 | 0.060 | 0.026 |
| 2017-01-05 | 0.060 | 0.031 |
| 2016-12-22 | 0.060 | 0.034 |
| 2016-12-08 | 0.060 | 0.034 |
| 2016-07-07 | 0.060 | 0.034 |
| 2016-06-03 | 0.060 | 0.036 |
| 2016-06-02 | 0.060 | 0.036 |
| 2016-01-07 | 0.060 | 0.041 |
| 2015-12-18 | 0.060 | 0.045 |
| 2015-07-09 | 0.060 | 0.039 |
| 2015-06-05 | 0.060 | 0.034 |
| 2015-06-04 | 0.060 | 0.034 |
| 2015-01-08 | 0.060 | 0.034 |
| 2014-12-19 | 0.060 | 0.037 |
| 2014-12-04 | 0.060 | 0.037 |
| 2014-07-10 | 0.060 | 0.038 |
| 2014-06-06 | 0.060 | 0.043 |
| 2014-06-05 | 0.060 | 0.045 |
| 2014-01-08 | 0.060 | 0.046 |
| 2013-12-20 | 0.060 | 0.048 |
| 2013-12-05 | 0.060 | 0.049 |
| 2013-07-11 | 0.060 | 0.046 |
| 2013-06-07 | 0.060 | 0.050 |
| 2013-06-06 | 0.060 | 0.052 |
| 2013-01-08 | 0.060 | 0.057 |
| 2012-12-20 | 0.060 | 0.064 |
| 2012-07-12 | 0.060 | 0.068 |
| 2012-06-08 | 0.060 | 0.076 |
| 2012-06-07 | 0.060 | 0.076 |
| 2012-01-05 | 0.060 | 0.075 |
| 2011-12-16 | 0.060 | 0.086 |
| 2011-12-08 | 0.060 | 0.092 |
| 2011-07-13 | 0.060 | 0.085 |
| 2011-06-03 | 0.060 | 0.078 |
| 2011-06-02 | 0.060 | 0.082 |
| 2011-01-06 | 0.060 | 0.090 |
| 2010-12-17 | 0.060 | 0.106 |
| 2010-12-07 | 0.060 | 0.104 |
| 2010-07-09 | 0.060 | 0.133 |
| 2010-06-04 | 0.060 | 0.154 |
| 2010-06-03 | 0.060 | 0.160 |
| 2010-01-08 | 0.060 | 0.158 |
| 2009-12-21 | 0.060 | 0.157 |
| 2009-12-08 | 0.060 | 0.163 |
| 2009-07-10 | 0.060 | 0.206 |
| 2009-06-05 | 0.060 | 0.229 |
| 2009-06-04 | 0.060 | 0.207 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cooper Companies is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
- Cooper Companies is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Income/ dividend checks
We assess Cooper Companies's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Cooper Companies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Cooper Companies has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $6,067,120 |
| AGE | 48 |
| TENURE AS CEO | 1 years |
CEO Bio
Mr. Albert G. White, III, has been President, Director and Chief Executive Officer of The Cooper Companies since May 1, 2018. Mr. White served as Chief Financial Officer of The Cooper Companies Inc. since November 1, 2016 until May 1, 2018. Mr. White served as the Chief Strategic Officer of The Cooper Companies Inc. since July 15, 2011 until May 1, 2018 and its Executive Vice President since December 2015 until May 1, 2018. He served as Chief Strategy Officer and Vice President of Investor Relations of CooperSurgical Inc., a subsidiary of The Cooper Companies Inc. He served as Senior Vice President of The Cooper Companies Inc. from November 2014 to December 22, 2015. Mr. White served as Vice President of The Cooper Companies Inc., from April 2006 to December 2012. He served as Treasurer and Vice President of Investor Relations of CooperSurgical Inc. He served as a Vice President of Investor Relations at The Cooper Companies Inc. since November 2007 until March 2013. He served as Treasurer at The Cooper Companies Inc. from April 10, 2006 to December 31, 2012. He served as Vice President of The Cooper Companies Inc. from April 10, 2006 to November 2007. Mr. White has been Cooper's primary relationship banker for 10 years. His experience includes corporate financings, acquisitions, private placements, strategic capital structure design and ancillary credit and non-credit products in both domestic and international markets. He joined Cooper from corporate and investment banking at Key Bank Capital Markets, where he served as Director in the Consumer Group and held number of leadership positions within KeyBank National Association for eight years. Mr. White received a Bachelor's Degree in Finance and a Master of Business Administration from Virginia Tech.
CEO Compensation
- Albert's compensation has increased by more than 20% in the past year.
- Albert's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Cooper Companies management team in years:
- The average tenure for the Cooper Companies management team is less than 2 years, this suggests a new team.
Management Team
Albert White
President
$6M
48
1 yrs
Brian Andrews
Senior VP
$1M
39
1 yrs
Dan McBride
Executive VP & COO
$4M
54
5.5 yrs
Holly Sheffield
Executive VP & Chief Strategy Officer
$3M
47
0.9 yrs
Bob Auerbach
President of Coopersurgical Inc
$1M
57
1.1 yrs
Agostino Ricupati
Senior VP of Finance & Tax and Chief Accounting Officer
$1M
51
1.6 yrs
Kim Duncan
Vice President of Investor Relations & Administration
Randy Golden
VP, General Counsel & Secretary
56
5.3 yrs
Juan Aragón
President of CooperVision Specialty EyeCare Division
1.3 yrs
Board of Directors Tenure
Average tenure and age of the Cooper Companies board of directors in years:
- The average tenure for the Cooper Companies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Tom Bender
Chairman
$492K
79
16.8 yrs
Albert White
President
$6M
48
1 yrs
Allan Rubenstein
Vice Chairman & Lead Director
$378K
73
16.8 yrs
Michael Kalkstein
Independent Director
$380K
75
27.3 yrs
Jody Lindell
Independent Director
$378K
67
13.3 yrs
Robert Weiss
Non-Independent Director
$6M
71
23.3 yrs
Gary Petersmeyer
Independent Director
$364K
71
6.3 yrs
Colleen Jay
Independent Director
$362K
55
3.1 yrs
Bill Kozy
Independent Director
$358K
66
3.1 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 02. Apr 19 | Sell | Jody Lindell | Individual | 01. Apr 19 | 01. Apr 19 | -2,943 | $296.80 | $-871,948 | ||
| 02. Apr 19 | Sell | Agostino Ricupati | Individual | 29. Mar 19 | 29. Mar 19 | -2,400 | $296.14 | $-710,722 | ||
| 27. Mar 19 | Sell | Brian Andrews | Individual | 25. Mar 19 | 25. Mar 19 | -1,648 | $293.28 | $-483,325 | ||
| 14. Mar 19 | Sell | Robert Auerbach | Individual | 12. Mar 19 | 12. Mar 19 | -2,272 | $292.22 | $-663,926 | ||
| 12. Mar 19 | Sell | Gary Petersmeyer | Individual | 08. Mar 19 | 08. Mar 19 | -799 | $286.88 | $-229,217 | ||
| 12. Mar 19 | Sell | Michael Kalkstein | Individual | 11. Mar 19 | 11. Mar 19 | -3,570 | $288.55 | $-1,030,121 | ||
| 12. Dec 18 | Buy | Allan Rubenstein | Individual | 10. Dec 18 | 10. Dec 18 | 348 | $241.60 | $84,075 | ||
| 01. Oct 18 | Sell | Randal Golden | Individual | 27. Sep 18 | 27. Sep 18 | -1,731 | $275.86 | $-477,510 | ||
| 13. Sep 18 | Sell | Allan Rubenstein | Individual | 13. Sep 18 | 13. Sep 18 | -1,500 | $265.37 | $-398,055 | ||
| 02. Jul 18 | Sell | Daniel McBride | Individual | 29. Jun 18 | 29. Jun 18 | -2,147 | $235.13 | $-504,820 | ||
| 25. Jun 18 | Sell | Gary Petersmeyer | Individual | 22. Jun 18 | 22. Jun 18 | -430 | $234.33 | $-100,764 | ||
| 19. Jun 18 | Sell | Allan Rubenstein | Individual | 15. Jun 18 | 15. Jun 18 | -1,000 | $235.13 | $-235,130 | ||
Management checks
We assess Cooper Companies's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Cooper Companies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Is It Time To Consider Buying The Cooper Companies, Inc. (NYSE:COO)?
Today we're going to take a look at the well-established The Cooper Companies, Inc. … saw its share price hover around a small range of $272.82 to $297.59 over the last few weeks? … Let’s take a look at Cooper Companies’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change
Simply Wall St - – Full articleCalculating The Fair Value Of The Cooper Companies, Inc. (NYSE:COO)
I will use the Discounted Cash Flow (DCF) model! … If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. … We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows
Simply Wall St - – Full articleThe Cooper Companies, Inc. (NYSE:COO): Can Growth Justify Its April Share Price?
Check out our latest analysis for Cooper Companies? … What can we expect from Cooper Companies in the future. … One reason why investors are attracted to COO is the high growth potential in the near future
Simply Wall St - – Full articleHow Good Is The Cooper Companies, Inc. (NYSE:COO) At Creating Shareholder Value?
In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … What is Return On Capital Employed (ROCE)? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.
Simply Wall St - – Full articleIs The Cooper Companies, Inc.'s (NYSE:COO) Balance Sheet A Threat To Its Future?
Let’s take a look at Cooper Companies’s leverage and assess its financial strength to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis … View our latest analysis for Cooper Companies
Simply Wall St - – Full articleDid Business Growth Power Cooper Companies's Share Price Gain of 128%?
One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price. … Cooper Companies's earnings per share are down 14% per year, despite strong share price performance over five years. … In contrast revenue growth of 8.8% per year is probably viewed as evidence that Cooper Companies is growing, a real positive.
Simply Wall St - – Full articleBased On Its ROE, Is The Cooper Companies, Inc. (NYSE:COO) A High Quality Stock?
This article is for those who would like to learn about Return On Equity (ROE). … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.042 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleDespite Its High P/E Ratio, Is The Cooper Companies, Inc. (NYSE:COO) Still Undervalued?
Based on the last twelve months, Cooper Companies's P/E ratio is 90.64. … How Do I Calculate Cooper Companies's Price To Earnings Ratio … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleIs There Now An Opportunity In The Cooper Companies, Inc. (NYSE:COO)?
saw significant share price movement during recent months on the NYSE, rising to highs of $281.66 and falling to the lows of $236.78. … Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price? … A question to answer is whether Cooper Companies's current trading price of $236.78 reflective of the actual value of the?
Simply Wall St - – Full articleDid The Cooper Companies Inc (NYSE:COO) Insiders Sell Shares?
That means that an insider was selling shares at below the current price (US$275). … All up, insiders sold more shares in Cooper Companies than they bought, over the last year … It's not ideal to see that insiders have sold at around the current price of US$275
Simply Wall St - – Full articleCompany Info
Description
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (ob/gyns) medical offices, and fertility clinics. In addition, the company offers carrier preimplantation genetic screening, preimplantation genetic diagnosis, and screening used in IVF process; micro pipettes; IVF medical devices and systems; and PARAGARD, a contraceptive option. It markets its products under Biofinity, clarity 1day, MyDay, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in Pleasanton, California.
Details
| Name: | The Cooper Companies, Inc. |
| COO | |
| Exchange: | NYSE |
| Founded: | 1980 |
| $14,356,024,074 | |
| 49,374,137 | |
| Website: | http://www.coopercos.com |
| Address: |
The Cooper Companies, Inc. 6140 Stoneridge Mall Road, Suite 590, Pleasanton, California, 94588, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | COO | Common Stock | New York Stock Exchange | US | USD | 21. Jan 1983 | |
| DB | CP6 | Common Stock | Deutsche Boerse AG | DE | EUR | 21. Jan 1983 | |
| LSE | 0I3I | Common Stock | London Stock Exchange | GB | USD | 21. Jan 1983 | |
| BMV | COO * | Common Stock | Bolsa Mexicana de Valores | MX | MXN | 21. Jan 1983 |
Number of employees
Current staff
Industry
| Health Care Supplies | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/16 01:20 |
| End of day share price update: | 2019/05/15 00:00 |
| Last estimates confirmation: | 2019/04/18 |
| Last earnings filing: | 2019/03/06 |
| Last earnings reported: | 2019/01/31 |
| Last annual earnings reported: | 2018/10/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
